Search Results - "Poehlau, D"

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review by Ziemssen, T, Rauer, S, Stadelmann, C, Henze, T, Koehler, J, Penner, I-K, Lang, M, Poehlau, D, Baier-Ebert, M, Schieb, H, Meuth, S

“…So far, clinical studies in primary progressive MS (PPMS) have failed to meet their primary efficacy endpoints. To some extent this might be attributable to…”
Get full text

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study by Schimrigk, S., Brune, N., Hellwig, K., Lukas, C., Bellenberg, B., Rieks, M., Hoffmann, V., Pöhlau, D., Przuntek, H.

“…An exploratory, prospective, open‐label study of fumaric acid esters (FAE, Fumaderm®) was conducted in patients with relapsing–remitting multiple sclerosis…”
Get full text

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study by Pöhlau, D., Przuntek, H., Sailer, M., Bethke, F., Koehler, J., König, N., Heesen, C., Späth, P., Andresen, I.

“…In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic…”
Get full text

Fluctuations of MS births and UV-light exposure by Verheul, F., Smolders, J., Trojano, M., Lepore, V., Zwanikken, C., Amato, M. P., Grand'Maison, F., Butzkueven, H., Marrosu, M., Duquette, P., Comi, G., Izquierdo, G., Grammond, P., Lus, G., Petersen, T., Bergamaschi, R., Giuliani, G., Boz, C., Coniglio, G., Van Pesch, V., Lechner-Scott, J., Cavalla, P., Granella, F., Avolio, C., Fiol, M., Poehlau, D., Saladino, M. L., Gallo, P., Deri, N., Oleschko Arruda, W., Paine, M., Ferro, M., Barnett, M., Cabrera-Gomez, J. A., Slee, M., Moore, F., Shaw, C., Petkovska-Boskova, T., Rutherford, M., Engelsen, O., Damoiseaux, J., Hupperts, R.

“…Background Patients with multiple sclerosis (MS) are more frequently born in spring when compared to autumn. Fluctuation of UV‐light has been hypothesized to…”
Get full text

Treatment of Chronic Progressive Multiple Sclerosis with Intravenous Immunoglobulins - interim Results on Drug Safety of an Ongoing Study by Poehlau, D

“…In a blinded administrative look we analyzed the safety profile of intravenous immunoglobulin (IVIG) treatment in an ongoing randomized, placebo controlled…”
Get full text

Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial by Poehlau, D, Federlein, J, Postert, T, Sailer, M, Bethke, F, Kappos, L, Haas, J, Przuntek, H

“…We present the design of a double-blind, randomised placebo-controlled phase III study to evaluate safety and efficacy of IVIG in the treatment of patients…”
Get more information

SCA2 alleles are not general predisposition factors for multiple sclerosis by Miterski, B, Eppelen, J T, Poehlau, D, Sindern, E, Haupts, M

Get full text

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis by Butzkueven, H, Chapman, J, Cristiano, E, Grand’Maison, F, Hoffmann, M, Izquierdo, G, Jolley, D, Kappos, L, Leist, T, Pöhlau, D, Rivera, V, Trojano, M, Verheul, F, Malkowski, J-P

“…Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional…”
Get full text

Therapeutic Immunoadsorption Increases the Level of Circulating Soluble HLA Molecules by Poehlau, D., Kiltz, U., Rieks, M., Hoffmann, V., Rebmann, V., Schimrigk, S., Grosse-Wilde, H., Przuntek, H.

“…Background and Objectives: Immunoadsorption (IA) is an established procedure to remove Igs and immune complexes from peripheral blood. Since Igs reportedly…”
Get full text

Photopheresis-A possible treatment of multiple sclerosis? Report of two cases by Poehlau, D., Rieks, M., Postert, T., Westerhausen, R., Busch, S., Hoffmann, K., Altmeyer, P., Przuntek, H.

Get full text

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry by Hughes, Stella, Spelman, Timothy, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Grand'Maison, Francois, Duquette, Pierre, Girard, Marc, Grammond, Pierre, Oreja-Guevara, Celia, Hupperts, Raymond, Boz, Cavit, Bergamaschi, Roberto, Giuliani, Giorgio, Rio, Maria Edite, Lechner-Scott, Jeannette, van Pesch, Vincent, Iuliano, Gerardo, Fiol, Marcela, Verheul, Freek, Barnett, Michael, Slee, Mark, Herbert, Joseph, Kister, Ilya, Vella, Norbert, Moore, Fraser, Petkovska-Boskova, Tatjana, Shaygannejad, Vahid, Jokubaitis, Vilija, McDonnell, Gavin, Hawkins, Stanley, Kee, Frank, Gray, Orla, Butzkueven, Helmut

“…BackgroundThe Expanded Disability Status Scale (EDSS) is widely used to rate multiple sclerosis (MS) disability, but lack of disease duration information…”
Get full text

Is α-methyldopa-type autoimmune hemolytic anemia mediated by interferon-γ? by BAIER, J. E, PEOHLAU, D

“…Drug-related autoimmune hemolytic anemia appearing with warm-reacting antibodies can be classified according to the offending substances. One of the subtypes…”
Get full text

Increasing age at disability milestones among MS patients in the MSBase Registry by Kister, Ilya, Chamot, Eric, Cutter, Gary, Bacon, Tamar E, Jokubaitis, Vilija G, Hughes, Stella E, Gray, Orla M, Trojano, Maria, Izquierdo, Guillermo, Grand'Maison, Francois, Duquette, Pierre, Lugaresi, Alessandra, Grammond, Pierre, Boz, Cavit, Hupperts, Raymond, Petersen, Thor, Giuliani, Giorgio, Oreja-Guevara, Celia, Iuliano, Gerardo, Lechner-Scott, Jeannette, Bergamaschi, Roberto, Rio, Maria Edite, Verheul, Freek, Fiol, Marcela, Van Pesch, Vincent, Slee, Mark, Butzkueven, Helmut, Herbert, Joseph

“…Abstract Objective To analyze time-trends in age at disability milestones among MS patients who were enrolled into the MSBase International Registry during…”
Get full text

Treatment of chronic progressive multiple sclerosis with intravenous immunoglobulins--interim results on drug safety of an ongoing study. IVIG study group by Poehlau, D

“…In a blinded administrative look we analyzed the safety profile of intravenous immunoglobulin (IVIG) treatment in an ongoing randomized, placebo controlled…”
Get full text

Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population by Twork, S., Nippert, I., Scherer, P., Haas, J., Pöhlau, D., Kugler, J.

“…ABSTRACT Objective: To assess the compliance, satisfaction and adverse effects of immunomodulating drugs in a German multiple sclerosis (MS) population…”
Get full text

Hippotherapy for multiple sclerosis - pilot study assessing effects on balance, spasticity, ability to walk and quality of life by Sager, A, Drache, M, Schaar, B, Poehlau, D

“…Background: Hippotherapy is a physiotherapeutic neurophysiological treatment that uses the movement of horses. The oscillating impulses of the…”
Get full text

Effects of acute psychological stress on adhesion molecules, interleukins and sex hormones: implications for coronary heart disease by HEINZ, Andreas, HERMANN, Derik, SMOLKA, Michael N, RIEKS, Maike, GRÄF, Klaus-Jürgen, PÖHLAU, Dieter, KUHN, Wilfried, BAUER, Michael

“…Subjects with high levels of daily stress suffer from an increased risk of coronary heart disease. Increased concentrations of the intercellular adhesion…”
Get full text

Health care needs of patients with multiple sclerosis in the first year after diagnosis by Eggers, J, Deistet, T, Poehlau, D, Oy, U H, von Schrader, J, Wilhelmi, H-D, Mattes, K, Fischbeck, S, Koehler, J

“…Background: Much is known about treatment in multiple sclerosis (MS), less about health care needs of the patients in the first year after diagnosis…”
Get full text

Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients by Hoffmann, V., Kuhn, W., Schimrigk, S., Islamova, S., Hellwig, K., Lukas, C., Brune, N., Pöhlau, D., Przuntek, H., Müller, T.

“…Available immunomodulatory and conventional steroid treatment regimens provide a limited symptomatic benefit for patients with progressive multiple sclerosis…”
Get full text

The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis by Butzkueven, H, Jolley, D, Trojano, M, Zwanikken, C, Grand'Maison, F, Duquette, P, Grammond, P, Bergamaschi, R, Giuliani, G, Timmermans, B, Boz, C, Rio, ME, Petersen, T, Poehlau, D

“…Background: The Multiple Sclerosis Severity Score (MSSS) is the Expanded Disability Status Scale (EDSS)-based severity rank for a given disease duration…”
Get full text